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INTRODUCTION
Resistance to diuretics, including furosemide, is frequent-
ly encountered in patients with nephrotic syndrome. The
overall response to a diuretic is determined by delivery of
drug to its site of action, delivery of solute to the site of
action, the dynamics of the drug with its receptor and
whether or not solute is reclaimed distal to the site of action
(1). Both pharmacokinetic and pharmacodynamic mecha-
nisms have been proposed as explanations for the resistance
to loop diuretics (2-4).
In plasma, furosemide is extensively bound to proteins,
mainly to albumin. The albumin-bound fraction of furo-
semide reaches the proximal tubule cells and is secreted into
the tubular lumen. Hypoalbuminemia diminishes the
amount of albumin-bound furosemide and diminishes the
furosemide delivery to the ascending limb of the loop of
Henle (5, 6). A reduction in the amount of pharmacologi-
cally active drug and an impairment of tubular reabsorption
due to urinary albumin-furosemide binding could ultimate-
ly diminish the diuretic effect (4, 7). Absolute or relative
hypovolemia in nephrotic syndrome may enhance NaCl
reabsorption and contribute to diuretic resistance (8).
Intravenous infusion of albumin in combination with
furosemide has been advocated as an effective method of
treating edema due to the nephrotic syndrome, but its clin-
ical efficacy is controversial (2, 3, 9, 10). Coadministration
of albumin with furosemide may improve furosemide deliv-
ery and hence diuretic effect by changing the pharmacoki-
netics of furosemide. Parallel infusion method of albumin
and furosemide was refuted by other opinion that optimal
efficacy of the combination could be achieved when furo-
semide was given after infusion of albumin, as the peak
furosemide concentrations would then coincide with maxi-
mal expansion of plasma volume (3, 11). However, we
demonstrated previously that a mixed infusion of albumin
and furosemide, compared with furosemide alone, did not
enhance the diuretic action of furosemide in six nephrotic
patients, either pharmacodynamically or pharmacokineti-
cally (12). Therefore, we tried to demonstrate some potenti-
ation by sequential infusion.
The present study was therefore undertaken to investigate
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Does Albumin Preinfusion Potentiate Diuretic Action of Furosemide
in Patients with Nephrotic Syndrome?
The aim of this cross-over study was to investigate whether albumin infusion
before furosemide administration could potentiate the diuretic action of
furosemide. Seven patients with nephrotic syndrome were given the following
infusions in random order on two separate days: 1) a sham solution followed by
160 mg of furosemide, 2) 100 mL of 20% human albumin followed by 160 mg of
furosemide. Urine and serum furosemide concentrations were measured by
high-performance liquid chromatography. The increment of urine volume was
greater in albumin preinfusion than in furosemide alone. However, the incre-
ments of sodium and chloride excretions between furosemide alone and albu-
min preinfusion were not different. No significant differences in the pharmacoki-
netic parameters between the two treatments were observed: area under the
concentration-time curve (AUC: 12.7±2.2 vs 15.1±4.4 g/mL∙hr), total plasma
clearance (253±41 vs 256±54 mL/min), volume of distribution (341±34 vs
494±153 mL/kg), elimination half life (4.0±1.1 vs 4.6±0.8 hr), and urine
furosemide excretion of the administered amount (16.5±7.3 vs 7.5±1.6%). In
conclusion, these data show that albumin preinfusion potentiated diuresis, but
not natriuresis, of furosemide without any change in the pharmacokinetics of the
agent in patients with nephrotic syndrome.
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whether albumin preinfusion to expand plasma volume
could improve the diuretic action of furosemide in patients
with nephrotic syndrome.
MATERIALS AND METHODS
Patients
This study was approved by the institutional review
board of Seoul National University Hospital. Seven patients
were enrolled after having given informed consent. They
exhibited generalized edema and the excretion of urinary
protein exceeded 3.5 g/1.73 m2/24 hr. Patients who were on
steroid treatments or who had taken diuretics within 48 hr
before the start of this study were excluded. Edematous
patients, with causes other than nephrotic syndrome (liver
cirrhosis, congestive heart failure, malnutrition, constrictive
pericarditis) were also excluded. Characteristics of the
patients are given in Table 1.
Study design
The study was performed as two way cross-over with a
washout period of two days. On each occasion, patients
were given no treatments as baseline. On the next day, they
were randomly given one of the two following infusions: 1)
100 mL of 5% dextrose water as a sham solution for albu-
min for 1 hr followed by 160 mg of furosemide (Lasix
�;
Handok Inc., Seoul, Korea) dissolved in 50 mL of dextrose
water for 30 min, 2) 100 mL of 20% human albumin
(Green Cross Co., Yong-In, Korea) for 1 hr followed by 160
mg of furosemide dissolved in 50 mL of dextrose water
solution for 30 min. All these infusions were given at 8 a.m.
over a period of 90 min.
All the patients were hospitalized and were placed on a
low-salt diet (salt<5 g/day) through the study period. For
the infusion and blood sampling, an indwelling cannula
was inserted into a vein in the left arm of each patient.
Urine was collected sequentially over 24 hr, from 9 a.m.
to 10 a.m. (0-1 hr), from 10 a.m. to noon (1-3 hr), from
noon to 3 p.m. (3-6 hr), from 3 p.m. to 9 p.m. (6-12 hr),
and from 9 p.m. to 9 a.m. of the next day (12-24 hr). An
effort was made to prevent undue exposure of urine samples
to light to prevent degradation of furosemide. Urine vol-
ume, osmolality, sodium and chloride excretions, and
furosemide excretion were measured. Blood samples were
taken for the determination of furosemide concentration at
10 a.m. (1 hr), noon (3 hr), 3 p.m. (6 hr), 9 p.m. (12 hr), and
9 a.m. of the next day (24 hr). Serum and urine samples for
the measurement of furosemide concentration were stored
at -70℃ immediately after sampling.
Measurements and Calculations
Urine osmolality was measured with a cryoscopic osmo-
meter (Osmomat 030-D-M; Gonotec, Berlin, Germany).
Urine sodium and chloride concentrations were measured
using an ion-selective method (System E4A; Beckman
Coulter Inc., Fullerton, CA, U.S.A.). The concentrations of
furosemide in urine and serum were measured with high-
performance liquid chromatography (HPLC) according to
the method described by Farthing et al. (13). The HPLC
system consisted of a pump (model 305; Gilson Inc., Vil-
liers Le Bel, France), a fluorescence detector (model S-3350;
Soma optics, Ltd., Japan), an integrator (Shimadzu Co.,
Kyoto, Japan), and an injector (model 7725i; Rheodyne,
Cotati, CA, U.S.A.). The analytic column was a 4- m-parti-
cle-sized Nova-Pak
� C18 column (300×3.9 mm, i.d.) from
Waters (Milford, MA, U.S.A.). The mobile phase of 10 mM
monobasic potassium phosphate buffer:acetonitrile (70:30,
v/v) was delivered at a flow rate of 1 mL/min. Acetonitrile
(HPLC grade) was used as received (Burdick and Jackson,
Muskegon, MI, U.S.A.). Monobasic potassium phosphate
(HPLC grade) was obtained from Merck KgaA (Darmstadt,
Germany). To measure the concentration of free furosemide
in urine, urine samples were centrifuged at 1,000 g for 10
min (GS-6 R; Beckman Coulter Inc., Fullerton, CA,
U.S.A.), after filtration through 14-mm diameter ultra-
filtration membranes (Diaflo
� 40420; Amicon Division,
W.R. Grace & Co., Conn. Berverly, MA, U.S.A.). The lower
limit of quantification (LLOQ) of furosemide concentration
in serum and urine was 0.025  g/mL. The day-to-day coef-
ficient of variations of serum and urine furosemide concen-
trations were 13% and 20%, respectively. 
Osmolal clearance was calculated using the following for-
Patient Age (yr) Sex Diagnosis Cr (mg/dL) Albumin (g/dL) 24-hr protein excretion (mg)
1 53 M FSGS 2.7 1.8 13475
2 23 M MC 1.2 1.6 17869
3 17 M FSGS 2.7 1.7 14965
4 74 M MPGN 1.6 2.1 7474
5 65 M MC 1.1 1.7 6972
6 20 M MC 1.2 1.4 10874
7 36 F FSGS 0.6 1.6 12060
Table 1. Patients characteristics
FSGS: focal segmental glomerulosclerosis; MC: minimal change; MPGN: membranoproliferative glomerulonephritis450 K.Y. Na, J.S. Han, Y.S. Kim, et al.
mula. 
Osmolal clearance=urine osmolality×urine volume/plas-
ma osmolality.
Free water clearance was calculated from urine volume
minus osmolal clearance. Noncompartmental pharmacoki-
netic analysis was performed using the WinNonlin stan-
dard version 2.1 program (Pharsight Co., Mountain View,
CA, U.S.A.). The area under the concentration-time curve
(AUC), total plasma clearance, elimination half life, and
volume of distribution were all calculated from the sequen-
tial change in the concentration of furosemide. The urinary
excretion rate of furosemide was calculated from the urine
volume and the concentration in urine, and was expressed as
a ratio (%) of the total administered dose.
Statistics
Differences between the effects of different treatments
were analyzed with Statview software (Abacus Concepts Inc.,
Berkeley, CA, U.S.A.) using Wilcoxon signed rank test. Val-
ues were presented as mean±SEM. Values of p<0.05 were
considered as indicative of statistical significance. 
RESULTS
Pharmacodynamic data
Both furosemide alone and furosemide after albumin
infusions increased urine volume significantly as compared
with each basal state. However, the volumes of urine
between furosemide alone and furosemide after albumin
infusions were not different. The osmolal clearance and the
free water clearance between the two groups were not sig-
nificantly different, either. Sodium and chloride excretions
were significantly increased in both groups, compared with
each basal state. However, the amounts of sodium and chlo-
ride excretions between the two groups were not different
(Table 2).
The increment of urine volume from basal state to post-
treatment state was greater in furosemide after albumin
infusions (1406±190 mL) than in furosemide alone (734
±224 mL). However, there was no difference in the incre-
ments of sodium excretions (110.5±23.6 mEq vs. 101.6
±33.3 mEq) and chloride excretions (127.4±26.1 mEq
vs. 132.3±36.8 mEq) between the two groups (Fig. 1).
Fig. 2 depicts the time course of sodium excretion. Albu-
min preinfusion had no effect on sodium excretion rate. The
urinary excretion rate of furosemide, which reflects the
amount reaching the site of action, is related to sodium
Basal Post-treatment Basal Post-treatment
Furosemide after albumin infusions Furosemide alone
Urine volume (mL/day) 996±230 1730±199a 646±91 2051±199b
Cosm* (mL/day) ND 1304±140 ND 1488±210
CH2O
�(mL/day) ND 403±136 ND 506±167
Urine Na (mEq/day) 19.0±7.2 129.5±29.6c 19.8±7.9 121.4±38.2d
Urine Cl (mEq/day) 39.1±12.4 166.4±29.2e 30.7±8.9 148.9±37.0f
Table 2. Pharmacodynamic data in furosemide alone and furosemide after albumin infusions
Data are expressed as mean±SEM (standard error of the mean). a-fp<0.05 by Wilcoxon signed rank test. *Osmolal clearance: 
� Free water clearance. 
ND: not done
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Fig. 1. Changes in 24-hr urine volume and sodium excretion in
the patients. The values depicted represent the differences
between basal and post-treatment states (mean±SEM). A:
Increment of urine volume. The increment of urine volume is
greater in furosemide after albumin infusions than in furosemide
alone (p<0.05). B: Increment of urinary sodium excretion. No dif-
ference is observed between the two treatments. 
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excretion rate (Fig. 3). Fig. 3 shows that this relationship
was not changed by albumin preinfusion.
Pharmacokinetic data
Table 3 shows the pharmacokinetic parameters from
furosemide alone versus furosemide after albumin infusions.
There was no significant differences of AUC, total plasma
clearance, volume of distribution, and elimination half life
between the two treatments. The amount of furosemide
delivered into the urine is more directly related to response
than is serum concentration of furosemide (14). Urine
furosemide excretions between the two treatments were not
different. Fig. 4 shows that albumin preinfusion had no effect
on the excretion rate of furosemide.
DISCUSSION
In this study, a significant increase in the volume of urine
was observed in patients with nephrotic syndrome when
albumin was infused before furosemide administration as
compared with administration of furosemide alone. The
potentiation of diuretic effect by albumin preinfusion was
not accompanied by any increase in sodium and chloride
excretion. This potentiation was not related to a change in
pharmacokinetics of furosemide, either. We speculate that
albumin preinfusion might expand plasma volume, which
might therefore have improved the diuretic action of furo-
semide.
In an attempt to overcome diuretic resistance in patients
with nephrotic syndrome, many trials of albumin coadmin-
istration have been conducted. Many of these studies revealed
that albumin had an additive diuretic effect. Davison et al.
and Eadington et al. reported positive results, but they did
not perform a cross-over study or show any pharmacokinet-
ic data (15, 11). Inoue et al. reported that effective diuresis
was achieved by infusion of the albumin-furosemide com-
plex in analbuminemic rats and hypoalbuminemic patients
(2). All the patients in their experiment were hypoalbu-
minemic due to causes other than nephrotic syndrome. It is
not certain therefore, whether their data could apply to the
study of nephrotic syndrome. Recently, it was reported that
coadministration of albumin moderately potentiated the
action of furosemide in patients with nephrotic syndrome
(10). In this study, the mean serum albumin concentration
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Fig. 2. Urinary sodium excretion rates in furosemide alone and
furosemide after albumin infusions.
Furosemide alone
Furosemide after albumin
infusions
Time (hr)
AUC ( g/mL-hr)  12.7±2.2 15.1±4.4
Total plasma clearance (mL/min) 253±41 256±54
Volume of distribution (mL/kg) 341±34 494±153
Elimination half life (hr) 4.0±1.1 4.6±0.8
Urine furosemide excretion (%) 16.5±7.3 7.5±1.6
Furosemide alone
Furosemide after
albumin infusions
Table 3. Pharmacokinetic data in furosemide alone and
furosemide after albumin infusions
AUC, area under the concentration-time curve. Data are expressed as
mean±SEM (standard error of the mean)
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Fig. 3. Relationship between furosemide excretion rate and sodi-
um excretion rate in furosemide alone and furosemide after
albumin infusions.
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Fig. 4. Furosemide excretion rates in furosemide alone and
furosemide after albumin infusions.
Time (hr)452 K.Y. Na, J.S. Han, Y.S. Kim, et al.
of patients was 2.9 g/dL and the mean 24-hr urine volume,
without administration of furosemide, was approximately 2
liters. The results of this experiment cannot be extrapolated
to morbid diuretic-resistant patients with more extreme
degrees of hypoalbuminemia. In our study, the mean serum
albumin concentration of the patients was 1.7 g/dL. In an
attempt to overcome the effect of diuretic-resistance, a
much higher dose of furosemide, 160 mg, was administered
to the patients. Furthermore, we measured pharmacokinetic
parameters of furosemide and found that potentiation of
diuretic effect was mediated by the changes of pharmacody-
namics, but not pharmacokinetics.
The cross-over study performed by Akcicek et al. demon-
strated that potentiation of the furosemide effect by infu-
sion of albumin did not occur (9). They simultaneously
infused furosemide 60 mg bolus followed by 40 mg/hr for 4
hr, and 20% albumin solution 0.5 mg/kg for 4 hr, to their
patients. At maximal doses of furosemide, albumin did not
facilitate any further increments in diuresis or natriuresis.
These results concur with the findings of our previous study
(11). We used maximal dose of furosemide, 160 mg, to
overcome diuretic-resistance. To improve delivery of the
drug, we mixed 160 mg of furosemide and 100 mL of 20%
albumin solution at room temperature before administra-
tion. This method of administration was previously used by
other investigators (2, 16). The timing of administration of
albumin and furosemide varied according to the investiga-
tors.
This study showed that albumin preinfusion increased
diuresis but not natriuresis that was provoked by furosemide.
There have been some reports that plasma volume expan-
sion, induced by albumin or dextran, caused an increase in
urine flow rate but not in sodium excretion in healthy vol-
unteers and in nephrotic patients (3, 17-19). This is impor-
tant given that an acute rise in blood volume suppresses
vasopressin secretion (20). The kidney shows of considerable
variations in urine flow in response to changing levels of
vasopressin. The large changes in urine flow are achieved
without substantial changes in osmolal clearance (21). We
calculated free water clearance and osmolal clearance to see
whether the increase of urine volume was due to water
diuresis or not. We found that the free water clearance as
well as the osmolal clearance in furosemide after albumin
infusions was slightly greater than in furosemide alone,
albeit without any statistical significance. Measurement of
vasopressin levels in patients could have given the clear
information about suppression of vasopressin secretion.
The diuretic effect of furosemide is directly related to the
amount and rate of the drug excreted in urine. The presence
of massive proteinuria and hypoalbuminemia in patients
with nephrotic syndrome alters the pharmacokinetics of
furosemide. The normal values of pharmacokinetic parame-
ters of furosemide are as follows: total plasma clearance, 200
mL/min; volume of distribution, 170-270 mL/kg; and
elimination half life, 45-60 min (22). In patients with
nephrotic syndrome, the binding of furosemide to plasma
proteins decreases in proportion with the reduction of plas-
ma albumin levels. At the same time, the volume of distri-
bution is apparently increased (23). In our analysis of phar-
macokinetic parameters from patients with nephrotic syn-
drome, total plasma clearance slightly increased (253
mL/min), volume of distribution increased (341 mL/kg),
and elimination half life was prolonged (4 hr). However,
there was no significant difference in clearance, volume of
distribution, and urinary furosemide excretion between furo-
semide alone and furosemide after albumin infusions. These
results indicate that the potentiation of diuresis by albumin
preinfusion is not relevant to the pharmacokinetics of
furosemide.
In animal studies, albumin in renal tubule fluid attenuat-
ed the effect of furosemide because the amount of pharma-
cologically active drug was reduced due to albumin-furo-
semide binding (4, 24). This was suggested as one of the
possible mechanisms to explain diuretic-resistance in pa-
tients with nephrotic syndrome. However, this suggestion
was argued against by the observation that unbound
furosemide in urine corresponded to the active furosemide
at its site of action. Furthermore, Agarwal et al. demon-
strated that displacement of urinary protein binding with
sulfisoxazole in nephrotic patients did not enhance response
to furosemide (25). Urinary protein binding of furosemide
is not a major mechanism of diuretic-resistance in nephrotic
syndrome. To measure the exact concentration of unbound
furosemide in urine, we filtered urine samples through
ultrafiltration membranes, which removed the substances
larger than 30 kDa.
The resistance of the nephron to loop diuretics is propor-
tional to the degree of hypoalbuminemia. This is due to an
overreabsorption of sodium by a stimulated and anatomical-
ly expanded basal labyrinth and an increased number of
sodium pumps in distal convoluted tubule, connecting
tubule, and cortical collecting duct (26), despite the defi-
cient proximal reabsorption of the molecule. Therefore, it
does not count whether sodium reabsorption in the proxi-
mal tubule or is blocked in the thick ascending limb by
furosemide, because the distal tubules adapt to this over-
load. Since thiazides inhibit the furosemide-induced overre-
absorption of sodium in distal tubule, coadministration of
furosemide and thiazide is commonly practiced to overcome
diuretic resistance (8).
There are several limitations in our study. Firstly, we did
not evaluate the exact plasma volume status by using
radioisotopes (e.g. 125I albumin) in the patients. It was
therefore not possible to assess any sequential changes in
plasma volume after albumin infusions. Secondly, as mea-
surements of glomerular filtration rate and effective renal
plasma flow using inulin and paraaminohippurate were not
performed, the renal hemodynamic changes in our patientsDoes Albumin Potentiate Diuretic Action of Furosemide? 453
remained unknown. Thirdly, had the findings of the renal
pathology been more uniform, the experiment would have
produced more consistent data. However, it was not practi-
cally easy to recruit patients with nephrotic syndrome and
with homogeneous pathology. Fourthly, three out of the
seven patients had reduced renal function. Complication of
azotemia is not uncommon in nephrotic patients. Because
abnormal renal function itself can alter the diuretic action of
furosemide, it is therefore possible that our data was con-
founded by the presence of azotemia. Lastly, when the dis-
tribution of furosemide is plotted, a two-compartmental
open model is usually used. In this study, however, we plot-
ted the pharmacokinetics using a noncompartmental model
because not all the individual data could be plotted ade-
quately using a two-compartment model. Noncompart-
mental analysis requires more frequent sampling intervals
than the intervals in our study. We are of an opinion, how-
ever, that these limitations had little adverse effects on the
reliability of our data.
As to the clinical management of patients with nephrotic
syndrome, it is more reasonable to increase the dose of
furosemide than to administer albumin (3, 9, 10). From
these results, taken together with our previous data (12), we
claim that albumin infusion before furosemide administra-
tion can be used to overcome diuretic-resistance patients
with nephrotic syndrome unresponsive to maximal doses of
furosemide.
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